Extract from the mushroom Agaricus blazei Murill har been shown to have strong
immunomodulating properties both in cell cultures, animal models and in humans.
Furthermore antitumor properties have been shown in animal models, among them in mice
with multiple myeloma. The investigators now want to investigate the effect of Agaricus
as supplementary treatment in addition to chemotherapy in patients with multiple myeloma.

Agaricus Blazei Murill in Patients With Multiple Myeloma

Multiple Myeloma

Patients who are scheduled to undergo high dose chemotherapy for multiple myeloma will
receive in addition in a double blinded manner 60 ml of agaricus extract or placebo once
daily from the start of stem cell mobilizing therapy until one week after the end of
aplasia after high dose melphalan.

Primary endpoints will be cytokine levels of degree of activation of tumor supressor
genes before and after start of the investigational product.

Secondary endpoints will be treatment response and quality of life.

Agaricus Blazei Murill in Patients With Multiple Myeloma

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?

Locations

Location

Status